



**ALERT**

## **NicOx's conference call Full Year End 2009 financial results and Worldwide Licensing Agreement with Bausch + Lomb for NCX 116**

---

TO: Investors, Analysts and Journalists

WHAT: **NicOx S.A. will release its full year 2009 financial results on March 4 at 5:30 pm CET (11:30 am EST – 4:30 pm UK) after the closing of the market trading in France.**

**NicOx will host a conference call to present its 2009 full year financial results, an update of the 2009 key achievements and the worldwide licensing agreement with Bausch + Lomb for NCX 116 in glaucoma.**

WHO: Michele Garufi, Chairman and CEO  
Eric Castaldi, Chief Financial Officer

WHEN: Thursday March 4, 2009 – 7:00 pm CET (6:00 pm UK – 11:00 am EST)

Phone number: +44 (0)207 153 2027 (for conference call and Q&A session). A presentation will be available on NicOx's website: [www.nicox.com](http://www.nicox.com).

A replay of the conference call will be available from March 4 until March 11. To listen to the replay, dial +44 (0) 207 959 6720 – Access code: 142626#

CONTACT: Karl Hanks, Director of Corporate Communications and Investor Relations  
Tel +33 (0)4 97 24 53 42 / [hanks@nicox.com](mailto:hanks@nicox.com)

Thanks to confirm your participation to Irène Lalande, Investor and Media Relations Coordinator. Tel: +33 (0)4 97 24 53 11 / [lalande@nicox.com](mailto:lalande@nicox.com)

---

**NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA)** is a pharmaceutical company focused on the research, development and future commercialization of drug candidates. NicOx is applying its proprietary nitric oxide-donating R&D platform to develop an internal portfolio of New Molecular Entities (NMEs) for the potential treatment of inflammatory, cardio-metabolic and ophthalmological diseases.

NicOx's lead investigational compound is naproxcinod, an NME and a first-in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-inflammatory drug candidate for the relief of the signs and symptoms of osteoarthritis. NicOx submitted a New Drug Application (NDA) for naproxcinod to the US Food and Drug Administration (FDA) in September 2009 and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in December 2009, following the successful completion of three pivotal phase 3 studies. The NDA for naproxcinod was accepted for filing by the FDA in November 2009 and the FDA has set a target date of July 24, 2010, for the completion of its review. The MAA was validated by the EMA in January 2010.

In addition to naproxcinod, NicOx's pipeline includes several nitric oxide-donating NMEs, which are in development internally and with partners, including Merck & Co., Inc. and Bausch + Lomb, for the treatment of widespread eye diseases, cardiometabolic diseases, hypertension and dermatological disease.

NicOx S.A. is headquartered in France and is listed on Euronext Paris (Compartment B: Mid Caps).

